

Louisiana Medicaid
Heart Disease – Pulmonary Arterial Hypertension (PAH)

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request prior authorization for non-preferred pulmonary arterial hypertension agents.

Additional Point-of-Sale edits may apply.

~~*Some of these agents medications in this therapeutic category*~~ may have **Black Box Warnings** and/or may be subject to **Risk Evaluation and Mitigation Strategy (REMS)** under FDA safety regulations. Please refer to individual prescribing information for details.

Approval Criteria for Initial and Reauthorization Requests

ALL of the following are required:

- ~~• For sildenafil oral suspension (generic for Revatio®) there has been a treatment failure or intolerable side effect with or contraindication to brand Revatio® oral suspension; AND~~
- There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; **AND**
- The requested medication has been prescribed for an approved diagnosis (see POS Edits); **AND**
- Previous use of a preferred product - **ONE** of the following is required:
 - The recipient has had a *treatment failure* with at least one preferred product; **OR**
 - The recipient has had an *intolerable side effect* to at least one preferred product; **OR**
 - The recipient has *documented contraindication(s)* to the preferred products that are appropriate to use for the condition being treated; **OR**
 - There is *no preferred product that is appropriate* to use for the condition being treated; **OR**
 - The prescriber states that the recipient is currently using the requested medication; **AND**
- By submitting the authorization request, the prescriber attests to the following:
 - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
 - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
 - The recipient has no concomitant drug therapies or disease states that limit the use of the requested medication and will not be receiving the requested medication in combination with any other medication that is contraindicated or not recommended per FDA labeling.

Duration of initial and reauthorization approval: 12 months

References

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; Retrieved from <https://www.clinicalkey.com/pharmacology/>

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach, 10e New York, NY: McGraw-Hill; Retrieved from <https://accesspharmacy.mhmedical.com/book.aspx?bookid=1861>

Adecira (tadalafil) [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2017. http://pi.lilly.com/us/adcireca_pi.pdf

Adempas (riociguat) [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; January 2018. https://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf

Letairis (ambrisentan) [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2019. https://www.letairis.com/patients/open-pdf?file=http://www.gilead.com/~-/media/Files/pdfs/medicines/cardiovascular/letairis/letairis_pi.pdf

Opsumit (macitentan) [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; April 2019. <https://www.opsumit.com/opsumit-prescribing-information.pdf>

Orenitram ER (treprostini) [package insert]. Research Triangle Park, NC: United Therapeutics Corp; January 2017. https://orenitram.com/pdf/Orenitram_Full_Prescribing_Information.pdf

Revatio (sildenafil) [package insert]. New York, NY: Pfizer Laboratories Division of Pfizer Inc; January 2019. <http://labeling.pfizer.com/showlabeling.aspx?id=645>

Tracleer (bosentan) [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; May 2019. https://www.tracleer.com/assets/PDFs/Tracleer_Full_Prescribing_Information.pdf

Tyvaso (treprostini) [package insert]. Research Triangle Park, NC: United Therapeutics Corp; October 2017. <https://www.tyvaso.com/hep/pdf/Tyvaso-PI.pdf?v=102017>

Uptravi (selexipag) [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; September 2019. <https://www.uptravihep.com/assets/pdf/uptravi-full-prescribing-information.pdf>

Ventavis (iloprost) [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; October 2017. https://www.4ventavis.com/pdf/Ventavis_PI.pdf

Revision / Date	Date Implementation Date
Single PDL Implementation	May 2019
Separated “Select Therapeutic Classes (Established)” into individual therapeutic class documents / November 2019	November 2019 / January 2020

Added wording requiring use of preferred brand Revatio® oral suspension, formatting changes / July 2020	July 2020
Removed wording for previous use of Revatio® oral suspension, formatting changes / April 2021;	April 2021 July 2021